FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208275512> ?p ?o ?g. }

• W3208275512 endingPage "1856" @default.
• W3208275512 startingPage "1856" @default.
• W3208275512 abstract "<h3>Importance</h3> Geriatric (aged ≥80 years) patients are historically underrepresented in cancer clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in geriatric patients. These agents are associated with immune-related adverse events (irAEs), which may be particularly associated with morbidity in this population. <h3>Objective</h3> To provide insight into the clinical outcomes and safety of ICIs among geriatric patients (aged ≥80 years) with cancer. <h3>Design, Setting, and Participants</h3> A Multicenter, international retrospective study of 928 geriatric patients with different tumors treated with single-agent ICIs between 2010 to 2019 from 18 academic centers in the US and Europe. Analyses were conducted from January 2021 to April 2021. <h3>Main Outcomes and Measures</h3> Clinical outcomes and irAE patterns in geriatric patients treated with single-agent ICIs. <h3>Results</h3> Median (range) age of the 928 patients at ICI initiation was 83.0 (75.8-97.0) years. Most patients (806 [86.9%]) were treated with anti–programmed cell death 1 therapy. Among the full cohort, the 3 most common tumors were non–small cell lung cancer (NSCLC, 345 [37.2%]), melanoma (329 [35.5%]), and genitourinary (GU) tumors (153 [16.5%]). Objective response rates for patients with NSCLC, melanoma, and GU tumors were 32.2%, 39.3%, and 26.2%, respectively. Median PFS and OS, respectively, were 6.7 and 10.9 months (NSCLC), 11.1 and 30.0 months (melanoma), and 6.0 and 15.0 months (GU). Within histologically specific subgroups (NSCLC, melanoma, and GU), clinical outcomes were similar across age subgroups (aged <85 vs ≥85 years). Among all 928 patients, 383 (41.3%) experienced ≥1 irAE(s), including 113 (12.2%) that were reported to be grade (G) 3 to 4 based on Common Terminology Criteria for Adverse Events (version 5.0). The median time to irAE onset was 9.8 weeks; 219 (57%) occurred within the first 3 months after ICI initiation. Discontinuation of treatment with ICIs owing to irAEs occurred in 137 (16.1%) patients. There was no significant difference in the rate of irAEs among patients aged younger than 85, 85 to 89, and 90 years or older. Despite the similar rate of G3 or higher irAEs, ICIs were discontinued due to irAEs more than twice as often among patients aged 90 years or older compared with patients younger than 90 years (30.9% vs 15.1%,<i>P</i> = .008). <h3>Conclusions and Relevance</h3> The findings of this international cohort study suggest that treatment with ICIs may be effective and generally well tolerated among older patients with cancer, though ICI discontinuation owing to irAEs was more frequent with increasing age." @default.
• W3208275512 created "2021-11-08" @default.
• W3208275512 creator A5001568490 @default.
• W3208275512 creator A5004779245 @default.
• W3208275512 creator A5006468163 @default.
• W3208275512 creator A5008845495 @default.
• W3208275512 creator A5009737345 @default.
• W3208275512 creator A5012176145 @default.
• W3208275512 creator A5013441605 @default.
• W3208275512 creator A5013768705 @default.
• W3208275512 creator A5013913173 @default.
• W3208275512 creator A5017302019 @default.
• W3208275512 creator A5020594501 @default.
• W3208275512 creator A5021158045 @default.
• W3208275512 creator A5024385167 @default.
• W3208275512 creator A5025067315 @default.
• W3208275512 creator A5025723323 @default.
• W3208275512 creator A5027390832 @default.
• W3208275512 creator A5029398339 @default.
• W3208275512 creator A5030450694 @default.
• W3208275512 creator A5037844360 @default.
• W3208275512 creator A5039797735 @default.
• W3208275512 creator A5040796539 @default.
• W3208275512 creator A5041977580 @default.
• W3208275512 creator A5042989547 @default.
• W3208275512 creator A5047645174 @default.
• W3208275512 creator A5048681236 @default.
• W3208275512 creator A5050938952 @default.
• W3208275512 creator A5052504518 @default.
• W3208275512 creator A5054901630 @default.
• W3208275512 creator A5055833911 @default.
• W3208275512 creator A5056211996 @default.
• W3208275512 creator A5057343975 @default.
• W3208275512 creator A5060954139 @default.
• W3208275512 creator A5063498997 @default.
• W3208275512 creator A5066642925 @default.
• W3208275512 creator A5070016877 @default.
• W3208275512 creator A5070044404 @default.
• W3208275512 creator A5070470707 @default.
• W3208275512 creator A5073007668 @default.
• W3208275512 creator A5073541359 @default.
• W3208275512 creator A5075756493 @default.
• W3208275512 creator A5080124352 @default.
• W3208275512 creator A5080682658 @default.
• W3208275512 creator A5086247944 @default.
• W3208275512 creator A5090621600 @default.
• W3208275512 creator A5091280788 @default.
• W3208275512 date "2021-12-01" @default.
• W3208275512 modified "2023-10-07" @default.
• W3208275512 title "Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer" @default.
• W3208275512 cites W2342631834 @default.
• W3208275512 cites W2610766845 @default.
• W3208275512 cites W2808441345 @default.
• W3208275512 cites W2886819625 @default.
• W3208275512 cites W2891486030 @default.
• W3208275512 cites W2964650688 @default.
• W3208275512 cites W2999905840 @default.
• W3208275512 cites W3021418236 @default.
• W3208275512 cites W3037716626 @default.
• W3208275512 cites W3131289431 @default.
• W3208275512 cites W3172071830 @default.
• W3208275512 cites W4254320293 @default.
• W3208275512 doi "https://doi.org/10.1001/jamaoncol.2021.4960" @default.
• W3208275512 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8569601" @default.
• W3208275512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34734989" @default.
• W3208275512 hasPublicationYear "2021" @default.
• W3208275512 type Work @default.
• W3208275512 sameAs 3208275512 @default.
• W3208275512 citedByCount "51" @default.
• W3208275512 countsByYear W32082755122021 @default.
• W3208275512 countsByYear W32082755122022 @default.
• W3208275512 countsByYear W32082755122023 @default.
• W3208275512 crossrefType "journal-article" @default.
• W3208275512 hasAuthorship W3208275512A5001568490 @default.
• W3208275512 hasAuthorship W3208275512A5004779245 @default.
• W3208275512 hasAuthorship W3208275512A5006468163 @default.
• W3208275512 hasAuthorship W3208275512A5008845495 @default.
• W3208275512 hasAuthorship W3208275512A5009737345 @default.
• W3208275512 hasAuthorship W3208275512A5012176145 @default.
• W3208275512 hasAuthorship W3208275512A5013441605 @default.
• W3208275512 hasAuthorship W3208275512A5013768705 @default.
• W3208275512 hasAuthorship W3208275512A5013913173 @default.
• W3208275512 hasAuthorship W3208275512A5017302019 @default.
• W3208275512 hasAuthorship W3208275512A5020594501 @default.
• W3208275512 hasAuthorship W3208275512A5021158045 @default.
• W3208275512 hasAuthorship W3208275512A5024385167 @default.
• W3208275512 hasAuthorship W3208275512A5025067315 @default.
• W3208275512 hasAuthorship W3208275512A5025723323 @default.
• W3208275512 hasAuthorship W3208275512A5027390832 @default.
• W3208275512 hasAuthorship W3208275512A5029398339 @default.
• W3208275512 hasAuthorship W3208275512A5030450694 @default.
• W3208275512 hasAuthorship W3208275512A5037844360 @default.
• W3208275512 hasAuthorship W3208275512A5039797735 @default.
• W3208275512 hasAuthorship W3208275512A5040796539 @default.
• W3208275512 hasAuthorship W3208275512A5041977580 @default.
• W3208275512 hasAuthorship W3208275512A5042989547 @default.
• W3208275512 hasAuthorship W3208275512A5047645174 @default.
• W3208275512 hasAuthorship W3208275512A5048681236 @default.

• next